Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

100
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
100
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.

JAMA cardiology·2026
Same author

Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.

JACC. Heart failure·2026
Same author

Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction.

JAMA cardiology·2026
Same author

Effect of Early Financial Support on Medication Adherence Among Low-Income Patients Following Heart Failure Hospitalization: The FUND-HF Pilot Trial.

Journal of the American College of Cardiology·2026
Same author

Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.

JACC. Heart failure·2026
Same author

Natriuretic Peptide-Based Screening for Heart Failure Among Adults With Diabetes: A Multicenter U.S. Experience.

JACC. Heart failure·2026

Related Experiment Video

Updated: Jul 25, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

662

Predicting and preventing heart failure in type 2 diabetes.

Ambarish Pandey1, Muhammad Shahzeb Khan2, Kershaw V Patel3

  • 1Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

The Lancet. Diabetes & Endocrinology
|June 29, 2023
PubMed
Summary

Heart failure is a growing concern for individuals with type 2 diabetes, leading to poorer health outcomes. This review explores the pathophysiology, risk factors, and prevention strategies for heart failure in type 2 diabetes patients.

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

226
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Related Experiment Videos

Last Updated: Jul 25, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

662
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

226
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Heart failure (HF) burden is rising globally in patients with type 2 diabetes (T2D).
  • Comorbid T2D and HF are associated with significantly worse clinical outcomes, including increased hospitalizations and mortality.
  • Optimal HF prevention strategies are crucial for this high-risk population.

Purpose of the Study:

  • To elucidate the pathophysiology and identify risk factors for HF in individuals with T2D.
  • To review risk assessment tools for predicting HF incidence in T2D.
  • To evaluate the efficacy of lifestyle and pharmacological interventions for HF prevention in T2D.

Main Methods:

  • Comprehensive literature review of pathophysiology, risk factors, and clinical trial data.
  • Analysis of risk assessment tools and management strategies.
  • Discussion of implementation challenges and recommendations.

Main Results:

  • Type 2 diabetes significantly increases the risk and severity of heart failure through complex pathophysiological mechanisms.
  • Several risk factors contribute to HF development in T2D, necessitating targeted assessment.
  • Clinical trials demonstrate the potential of lifestyle modifications and specific pharmacological agents in mitigating HF risk.

Conclusions:

  • Understanding the intricate link between T2D and HF is vital for effective prevention.
  • Early risk identification and tailored interventions, including lifestyle changes and evidence-based medications, are key.
  • Addressing implementation barriers is essential for widespread adoption of improved management approaches.